Salute e Benessere

Zinzino AB (publ.): Preliminary Sales Report Q3 2025

Revenue in Zinzino's sales markets increased by 54 % in the third quarter of 2025 compared with the same period last year and amounted to SEK 777.3 (504.4) million. Total revenues in the Group increased by 48% in the third quarter and amounted to SEK 786.7 (532.8) million. Revenue in Zinzino's sales markets increased by 54 % in the third quarter of 2025 compared with the same period last year and amounted toSEK 777.3(504.4) million. Total revenues in the Group increased by 48% in the third...
PR Newswire
03/10/2025

The Department of Clinical and Molecular Medicine of Sapienza University of…

Following a successful proof-of-concept using model cells, the collaboration now moves into a clinical phase. Blood samples from lung cancer patients will be collected at Sant'Andrea Hospital in Rome and processed at DMCM where Tethis' See.d instrument has been installed. The instrument will produce cytology slides containing cells, including CTCs. These slides will then be sent to Tethis, where they will be stained with Takis' HER3-specific antibody, enabling the identification of HER3-positive…
PR Newswire
03/10/2025

Appointment of Marc Le Bozec as Interim CEO

Appointment of Marc Le Bozec as Interim CEO Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE)announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors.The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer.The Board of Directors has empowered Marc Le Bozec...
Nasdaq GlobeNewswire
03/10/2025

A New Era of Modest Elegance: Royals Unveil Three Muslim-Friendly Lifestyle…

The three brands reflect the spirit of modest elegance, each carrying the unique vision of its founder: The three brands reflect the spirit of modest elegance, each carrying the unique vision of its founder: NARA, founded byYang Mulia Tengku Khairul Adena, embodies timeless luxury and sophistication. With a focus on handbags and cosmetics, NARA blends heritage and modernity to create statement pieces. Inspired by her vision to empower women with confidence and individuality, the brand...
PR Newswire
03/10/2025

FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance…

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study 1 First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC 2 Regimen recommended in National Comprehensive Cancer Network® Guidelines for SCLC* 3 Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug...
Nasdaq GlobeNewswire
03/10/2025

Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment…

Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and only approved therapy for DMD in Canada Pratteln, Switzerland, October 3, 2025 –Santhera Pharmaceuticals (SIX: SANN) today notes that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older following Priority Review, marking the first approved...
Nasdaq GlobeNewswire
03/10/2025

Change in the Roche Board of Directors

Dr. Süssmuth Dyckerhoff has served on the Board of Directors since March 2016.Roche Chairman Severin Schwan: "Claudia’s profound knowledge of the healthcare industry and her deep understanding of international market dynamics, particularly in Asia, have resulted in significant contributions to the success of Roche. On behalf of the Board, I would like to sincerely thank Claudia for her dedication to Roche over the past decade and wish her all the best for the future.” About Roche...
Nasdaq GlobeNewswire
03/10/2025

MedHub-AI Announces National Reimbursement Approval in Japan for AutocathFFR™

Addressing a Critical Healthcare Need Addressing a Critical Healthcare Need Coronary artery disease is the number one cause of morbidity and mortality worldwide, including inJapanwhere the burden of cardiovascular disease continues to rise. The introduction of AI-driven, non-invasive physiology represents an important advancement for both clinicians and patients by supporting evidence-based decision-making, reducing procedural complexity, and potentially lowering overall healthcare...
PR Newswire
03/10/2025

Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the…

Graves' Orbitopathy Market Summary Graves' Orbitopathy Market Summary Discover the new Graves' orbitopathy treatment @Graves' Orbitopathy Treatment Market Key Factors Driving the Growth of the Graves' Orbitopathy Market Rising Graves' Orbitopathy Prevalence According to DelveInsight analysis, there were approximately 1.4 million diagnosed prevalent cases of Graves' orbitopathy in the 7MM in 2024, with the number projected to rise by 2034. In 2024, the US reported that...
PR Newswire
02/10/2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – October 2, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notification as follows: Oxurion received a transparency notification on October 2, 2025, from Atlas Special Opportunities II…
Actusnews Wire
02/10/2025

HELFIE AI BOLSTERS INNOVATION AND MEDICAL EXPERTISE WITH NEW CHIEF MEDICAL…

Habash co-founded HipaaChat and served as Chief Medical Officer of Everbridge, where she helped scale secure messaging and telemedicine platforms to over 1,500 hospitals while collaborating with leading technology companies like Apple, Amazon, and Verizon to modernize healthcare communications. At Microsoft Healthcare, she partnered with their healthcare team to lead a large AI initiative, generating multi-disease retinal algorithms for autonomous diagnosis of eye conditions and built a global…
PR Newswire
02/10/2025

Aid cannot wait - Hydrachem urges global action to break barriers to clean water

Nicolas Barbieri, Chief Commercial Officer at Hydrachem, commented: Nicolas Barbieri, Chief Commercial Officer atHydrachem, commented: "A global commitment to humanitarian aid is meaningless if we cannot get what is needed into the hands of vulnerable communities. In every crisis we see the same pattern: water supplies are destroyed or contaminated, disease spreads and aid agencies race against time to prevent countless deaths. We have the technology to make water safe, but we are...
PR Newswire
02/10/2025

XenoSTART and Minerva Imaging Expand Partnership to Deliver Integrated…

Radiopharmaceuticals are one of the fastest-growing areas in oncology, redefining how we treat cancer by precisely targeting tumors while sparing healthy tissue. In metastatic prostate cancer, these therapies are already changing standards of care and are now being explored in earlier disease stages and across other high-burden indications such as breast and neuroendocrine tumors. This expansion is driving an urgent need for robust, translational platforms that can shorten timelines and de-risk…
PR Newswire
02/10/2025

ERS 2025: BMC Showcases Innovation, Collaboration and a Future of Better…

At the BMC-sponsored Skills Lab: The Future of CPAP Monitoring – What Needs to Change Today? leading experts called for a shift beyond the traditional "4 hours/night" compliance metric. At the BMC-sponsoredSkills Lab: The Future of CPAP Monitoring – What Needs to Change Today?leading experts called for a shift beyond the traditional"4 hours/night"compliance metric. The session drew a nearly full room and sparked wide discussions across the ERS community, underscoring the…
PR Newswire
02/10/2025

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for…

AAVB-039 addresses the root cause of the disease, benefitting patients with any ABCA4 mutationAAVB-039 is currently being assessed in the CELESTE interventional clinical trial and we continue recruiting in our STELLA observational studyMILAN, Oct.02, 2025(GLOBE NEWSWIRE) --AAVantgarde Bio(AAVantgarde), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Nasdaq GlobeNewswire
02/10/2025

Personalized Nutrition Market worth $30.94 billion by 2030- Exclusive Report by…

Browse in-depth TOC on "Personalized Nutrition Market" Browse in-depth TOC on "Personalized Nutrition Market" 100 – Tables 70 – Figures 250 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249208030 Within product segment, digital tools and platforms to capture significant market share Digital tools and platforms are becoming the fastest-growing product segment in personalized nutrition, driven by scalable, data-centric, and...
PR Newswire
02/10/2025

ExQor Technologies Announces Advancement Toward Clinical Trials for Brain…

ExQor Technologies, a Boston MA based biotechnology company, is preparing for clinical trials for its proprietary brain regenerative medicine platform targeting Alzheimer's disease. Current Alzheimer's therapeutics are limited to slowing cognitive decline, but the company's preclinical data demonstrates something fundamentally different – the ability to reverse brain damage and promote regeneration. An additional trial is planned for frontotemporal dementia, while exploring other conditions…
PR Newswire
02/10/2025

AorticLab Receives FDA Approval to Initiate FLOWer™ Clinical Pivotal…

"FDA approval of the FLOWer IDE marks a major milestone for AorticLab , with the aim of providing also to the US patients a safe and effective device to improve outcome of structural heart interventions" said Franco Osta, CEO of AorticLab. "FDA approval of the FLOWer IDE marks a major milestone for AorticLab, with the aim of providing also to the US patients a safe and effective device to improve outcome of structural heart interventions" said Franco Osta, CEO of AorticLab…
PR Newswire
02/10/2025

Medtecs Showcases Global Capabilities at MEDICA and A+A in Germany

Medtecs strengthens its global market leadership with robust production capacity and international certifications. This year, the company partnered with leading glove manufacturer Hongray Group to jointly operate one of Cambodia's first FDA-certified international-level NBR glove facility. Running 24/7 at full capacity, the plant combines tariff advantages outside China with vertical integration from latex to packaging, enhancing competitiveness and supply resilience. The partnership reinforces…
PR Newswire
02/10/2025

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System…

At the congress, Lundbeck will share Insights into the design of the Phase 3 MASCOT trial and its use of innovative Bayesian progression modeling methods.1,2 Rare diseases, such as MSA, face unique challenges due to limited prior data available to guide the design of drug development programs and smaller patient populations to enroll in trials.6,7 At the congress, Lundbeck will share Insights into the design of the Phase 3 MASCOT trial and its use of innovative Bayesian progression modeling…
PR Newswire
02/10/2025

Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali…

Press ReleaseNicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-planned analysis of the NCX 470 Denali trial completedNCX 470 maintains robust intraocular pressure lowering at 6, 9 and 12 monthsOther analyses broadly in line with the trends seen for Mont BlancData presentations planned for upcoming ophthalmology conferencesOctober 2, 2025 – release at 7:30 am CETSophia...
Nasdaq GlobeNewswire
02/10/2025

CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and…

Key Takeaways from the CXCR Inhibitors Market Report Key Takeaways from the CXCR Inhibitors Market Report Discover which indication is expected to grab the major CXCR inhibitors market share @CXCR Inhibitors Market Report Key Factors Driving the CXCR Inhibitors Market Rising Oncology and Hematologic Disease Burden The growing incidence of cancers and hematologic malignancies increases demand for targeted therapies that address metastasis, chemo-resistance, and stem-cell...
PR Newswire
01/10/2025

Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share…

The tender offer period will expire at one minute after 11:59 p.m., New York City time on October 29, 2025, unless the offer is extended.Roche has filed a tender offer statement on Schedule TO with the United States Securities and Exchange Commission (SEC). Bluefin Merger Subsidiary, Inc. is the acquirer in the tender offer. The Offer to Purchase contained within the Schedule TO sets out the terms and conditions of the tender offer.89bio has also filed a Solicitation/Recommendation...
Nasdaq GlobeNewswire
01/10/2025

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3)…

Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective response rate (ORR); 6 complete responses and 3 partial responsesRecruitment of 17 additional patients is ongoing as plannedData presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1 stPARIS and CAMBRIDGE, Mass., Oct.01, 2025...
Nasdaq GlobeNewswire
01/10/2025
Altri  Comunicati